Patents by Inventor Hugh Y. Rienhoff, Jr.

Hugh Y. Rienhoff, Jr. has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • KDM1A inhibitors for the treatment of disease
    Patent number: 11932629
    Abstract: The present disclosure relates to compounds and methods which may be useful as inhibitors of KDM1A for the treatment or prevention of diseases. Methods of inhibition of KDM1A, methods of increasing gamma globin gene expression, and methods to induce differentiation in cancer cells in a human or animal subject are also provided for treatment of disease such as acute myelogenous leukemia.
    Type: Grant
    Filed: December 15, 2022
    Date of Patent: March 19, 2024
    Assignee: Imago Biosciences, Inc.
    Inventors: Amy E. Tapper, Cassandra Celatka, Michael Clare, Hugh Y. Rienhoff, Jr.
  • KDM1A inhibitors for the treatment of disease
    Patent number: 11773068
    Abstract: Disclosed herein are new compounds and compositions and their application as pharmaceuticals for the treatment of diseases. Methods of inhibition of KDM1A, methods of increasing gamma globin gene expression, and methods to induce differentiation of cancer cells in a human or animal subject are also provided for the treatment of diseases such as acute myelogenous leukemia.
    Type: Grant
    Filed: September 22, 2021
    Date of Patent: October 3, 2023
    Assignee: Imago Biosciences, Inc.
    Inventors: Hugh Y. Rienhoff, Jr., John M. McCall, Michael Clare, Cassandra Celatka, Amy E. Tapper
  • KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE
    Publication number: 20230250090
    Abstract: The present disclosure relates to compounds and methods which may be useful as inhibitors of KDM1A for the treatment or prevention of diseases. Methods of inhibition of KDM1A, methods of increasing gamma globin gene expression, and methods to induce differentiation in cancer cells in a human or animal subject are also provided for treatment of disease such as acute myelogenous leukemia.
    Type: Application
    Filed: December 15, 2022
    Publication date: August 10, 2023
    Inventors: Amy E. TAPPER, Cassandra CELATKA, Michael CLARE, Hugh Y. RIENHOFF, JR.
  • KDM1A inhibitors for the treatment of disease
    Patent number: 11655226
    Abstract: Disclosed herein are new compounds and compositions and their application as pharmaceuticals for the treatment of diseases. Methods of inhibition of KDM1A, methods of increasing gamma globin gene expression, and methods to induce differentiation of cancer cells in a human or animal subject are also provided for the treatment of diseases such as acute myelogenous leukemia.
    Type: Grant
    Filed: December 1, 2020
    Date of Patent: May 23, 2023
    Assignee: Imago Biosciences, Inc.
    Inventors: John M. McCall, Hugh Y. Rienhoff, Jr., Michael Clare
  • KDM1A inhibitors for the treatment of disease
    Patent number: 11578059
    Abstract: The present disclosure relates to compounds and methods which may be useful as inhibitors of KDM1A for the treatment or prevention of diseases. Methods of inhibition of KDM1A, methods of increasing gamma globin gene expression, and methods to induce differentiation in cancer cells in a human or animal subject are also provided for treatment of disease such as acute myelogenous leukemia.
    Type: Grant
    Filed: May 13, 2019
    Date of Patent: February 14, 2023
    Assignee: Imago Biosciences. Inc.
    Inventors: Amy E. Tapper, Cassandra Celatka, Michael Clare, Hugh Y. Rienhoff, Jr.
  • LYSINE-SPECIFIC HISTONE DEMETHYLASE INHIBITORS FOR THE TREATMENT OF MYELOPROLIFERATIVE NEOPLASMS
    Publication number: 20230000835
    Abstract: Disclosed herein are methods for treating or preventing myeloproliferative neoplasms in a subject in need thereof, and for effecting specific clinically relevant endpoints, comprising administering a therapeutically effective amount of an LSD1 inhibitor.
    Type: Application
    Filed: June 2, 2022
    Publication date: January 5, 2023
    Inventor: Hugh Y. RIENHOFF, JR.
  • KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE
    Publication number: 20220073477
    Abstract: Disclosed herein are new compounds and compositions and their application as pharmaceuticals for the treatment of diseases. Methods of inhibition of KDM1A, methods of increasing gamma globin gene expression, and methods to induce differentiation of cancer cells in a human or animal subject are also provided for the treatment of diseases such as acute myelogenous leukemia.
    Type: Application
    Filed: September 22, 2021
    Publication date: March 10, 2022
    Inventors: Hugh Y. RIENHOFF, JR., John M. MCCALL, Michael CLARE, Cassandra CELATKA, Amy E. TAPPER
  • KDM1A inhibitors for the treatment of disease
    Patent number: 11230534
    Abstract: Disclosed herein are new compounds and compositions and their application as pharmaceuticals for the treatment of diseases. Methods of inhibition of KDM1A, methods of increasing gamma globin gene expression, and methods to induce differentiation of cancer cells in a human or animal subject are also provided for the treatment of diseases such as acute myelogenous leukemia.
    Type: Grant
    Filed: November 1, 2019
    Date of Patent: January 25, 2022
    Assignee: Imago Biosciences, Inc.
    Inventors: Hugh Y. Rienhoff, Jr., John M. McCall, Michael Clare, Cassandra Celatka, Amy E. Tapper
  • LYSINE-SPECIFIC HISTONE DEMETHYLASE INHIBITORS FOR THE TREATMENT OF MYELOPROLIFERATIVE NEOPLASMS
    Publication number: 20210386733
    Abstract: Disclosed herein are methods for treating or preventing myeloproliferative neoplasms in a subject in need thereof, and for effecting specific clinically relevant endpoints, comprising administering a therapeutically effective amount of an LSD1 inhibitor.
    Type: Application
    Filed: June 17, 2021
    Publication date: December 16, 2021
    Inventor: Hugh Y. RIENHOFF, JR.
  • LYSINE-SPECIFIC HISTONE DEMETHYLASE AS A NOVEL THERAPEUTIC TARGET IN MYELOPROLIFERATIVE NEOPLASMS
    Publication number: 20210196711
    Abstract: Disclosed herein are methods for treating or preventing myeloproliferative neoplasms in a subject in need thereof, and for effecting specific clinically relevant endpoints, comprising administering a therapeutically effective amount of an LSD1 inhibitor.
    Type: Application
    Filed: January 8, 2021
    Publication date: July 1, 2021
    Inventor: Hugh Y. RIENHOFF, JR.
  • KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE
    Publication number: 20210147373
    Abstract: Disclosed herein are new compounds and compositions and their application as pharmaceuticals for the treatment of diseases. Methods of inhibition of KDM1A, methods of increasing gamma globin gene expression, and methods to induce differentiation of cancer cells in a human or animal subject are also provided for the treatment of diseases such as acute myelogenous leukemia.
    Type: Application
    Filed: December 1, 2020
    Publication date: May 20, 2021
    Inventors: John M. MCCALL, Hugh Y. RIENHOFF, JR., Michael CLARE
  • KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE
    Publication number: 20210115023
    Abstract: The present disclosure relates to compounds and methods which may be useful as inhibitors of KDM1 A for the treatment or prevention of diseases. Methods of inhibition of KDM1 A, methods of increasing gamma globin gene expression, and methods to induce differentiation in cancer cells in a human or animal subject are also provided for treatment of disease such as acute myelogenous leukemia.
    Type: Application
    Filed: May 13, 2019
    Publication date: April 22, 2021
    Inventors: Amy E. TAPPER, Cassandra CELATKA, Michael CLARE, Hugh Y. RIENHOFF, Jr.
  • KDM1A inhibitors for the treatment of disease
    Patent number: 10882835
    Abstract: Disclosed herein are new compounds and compositions and their application as pharmaceuticals for the treatment of diseases. Methods of inhibition of KDM1A, methods of increasing gamma globin gene expression, and methods to induce differentiation of cancer cells in a human or animal subject are also provided for the treatment of diseases such as acute myelogenous leukemia.
    Type: Grant
    Filed: June 19, 2019
    Date of Patent: January 5, 2021
    Assignee: Imago Biosciences, Inc.
    Inventors: John M. McCall, Hugh Y. Rienhoff, Jr., Michael Clare
  • KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE
    Publication number: 20200283397
    Abstract: Disclosed herein are new compounds and compositions and their application as pharmaceuticals for the treatment of diseases. Methods of inhibition of KDM1A, methods of increasing gamma globin gene expression, and methods to induce differentiation of cancer cells in a human or animal subject are also provided for the treatment of diseases such as acute myelogenous leukemia.
    Type: Application
    Filed: November 1, 2019
    Publication date: September 10, 2020
    Inventors: Hugh Y. RIENHOFF, JR., John M. MCCALL, Michael CLARE, Cassandra CELATKA, Amy E. TAPPER
  • KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE
    Publication number: 20200095214
    Abstract: Disclosed herein are new compounds and compositions and their application as pharmaceuticals for the treatment of diseases. Methods of inhibition of KDM1A, methods of increasing gamma globin gene expression, and methods to induce differentiation of cancer cells in a human or animal subject are also provided for the treatment of diseases such as acute myelogenous leukemia.
    Type: Application
    Filed: June 19, 2019
    Publication date: March 26, 2020
    Inventors: John M. MCCALL, Hugh Y. RIENHOFF, Jr., Michael CLARE
  • KDM1A inhibitors for the treatment of disease
    Patent number: 10519118
    Abstract: Disclosed herein are new compounds and compositions and their application as pharmaceuticals for the treatment of diseases. Methods of inhibition of KDM1A, methods of increasing gamma globin gene expression, and methods to induce differentiation of cancer cells in a human or animal subject are also provided for the treatment of diseases such as acute myelogenous leukemia.
    Type: Grant
    Filed: April 12, 2018
    Date of Patent: December 31, 2019
    Assignee: Imago Biosciences, Inc.
    Inventors: Hugh Y. Rienhoff, Jr., John M. McCall, Michael Clare, Cassandra Celatka, Amy E. Tapper
  • KDM1A inhibitors for the treatment of disease
    Patent number: 10370346
    Abstract: Disclosed herein are new compounds and compositions and their application as pharmaceuticals for the treatment of diseases. Methods of inhibition of KDM1A, methods of increasing gamma globin gene expression, and methods to induce differentiation of cancer cells in a human or animal subject are also provided for the treatment of diseases such as acute myelogenous leukemia.
    Type: Grant
    Filed: August 2, 2017
    Date of Patent: August 6, 2019
    Assignee: Imago Biosciences, Inc.
    Inventors: John M. McCall, Hugh Y. Rienhoff, Jr., Michael Clare
  • LYSINE-SPECIFIC HISTONE DEMETHYLASE AS A NOVEL THERAPEUTIC TARGET IN MYELOPROLIFERATIVE NEOPLASMS
    Publication number: 20190070172
    Abstract: Disclosed herein are methods for treating or preventing myeloproliferative neoplasms in a subject in need thereof, and for effecting specific clinically relevant endpoints, comprising administering a therapeutically effective amount of an LSD1 inhibitor.
    Type: Application
    Filed: November 7, 2016
    Publication date: March 7, 2019
    Inventor: Hugh Y. RIENHOFF, Jr.
  • KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE
    Publication number: 20180312474
    Abstract: Disclosed herein are new compounds and compositions and their application as pharmaceuticals for the treatment of diseases. Methods of inhibition of KDM1A, methods of increasing gamma globin gene expression, and methods to induce differentiation of cancer cells in a human or animal subject are also provided for the treatment of diseases such as acute myelogenous leukemia.
    Type: Application
    Filed: April 12, 2018
    Publication date: November 1, 2018
    Inventors: Hugh Y. RIENHOFF, Jr., John M. MCCALL, Michael CLARE, Cassandra CELATKA, Amy E. TAPPER
  • KDM1A inhibitors for the treatment of disease
    Patent number: 9981922
    Abstract: Disclosed herein are new compounds and compositions and their application as pharmaceuticals for the treatment of diseases. Methods of inhibition of KDM1A, methods of increasing gamma globin gene expression, and methods to induce differentiation of cancer cells in a human or animal subject are also provided for the treatment of diseases such as acute myelogenous leukemia.
    Type: Grant
    Filed: February 12, 2016
    Date of Patent: May 29, 2018
    Assignee: Imago Biosciences, Inc.
    Inventors: Hugh Y. Rienhoff, Jr., John M. McCall, Michael Clare, Cassandra Celatka, Amy E. Tapper